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Abstract 
Aims: Episode of acute heart failure (AHF) unfavorably affects multiple organs which may have an 
adverse impact on the outcomes. We investigated the prevalence and clinical consequences of 
abnormal liver function tests (LFTs) in AHF patients enrolled in the PROTECT study.  
Methods and Results. LFTs comprised serial assessment of AST (Aspartate aminotransferase), 
ALT (Alanine Aminotransferase) and albumin at baseline and during follow up (daily until 
discharge, on day 7 and 14). Prevalence of abnormal LFTs (above upper limit of normal for AST 
and ALT or below lower limit of normal for albumin) was: at baseline AST- 20%, ALT- 12%, 
albumin- 40% and at Day-14: AST- 15%, ALT- 9%, albumin- 26%, respectively. Abnormal LFTs 
at baseline were associated with higher risk of in-hospital death with odds ratios (95% confidence 
interval [CI]) for AST 3.5 (1.7-7.3), for ALT 3.9 (1.8-8.4), and for albumin 2.8 (1.3-5.9) (all 
p<0.01). Abnormal baseline and discharge LFTs unfavorably impacted 180-day mortality with 
hazard ratios (95%CI) for baseline AST, ALT, albumin: 1.3 (1.0-1.7), 1.1 (1.0-1.2), 1.4 (1.1-1.8) 
and for discharge AST, ALT, albumin: 1.5 (1.1-2.0), 1.5 (1.0-2.2), 1.6 (1.2-2.1), respectively (all 
p<0.05). Analysis of LFTs trajectories (calculated as changes in LFTs over time) revealed that 
increasing AST and ALT on day-3 as well as decreasing albumin on day-4 were independent 
prognosticators of 180-day outcome (all p<0.05). 
Conclusions: Abnormal LFTs are frequent in AHF at baseline and during hospital stay, and predict 
worse outcomes. Whether this association is causal, and which are the underlying mechanisms 
involved, require further study.    
Key words: acute heart failure, liver dysfunction, prognosis, liver function tests.  
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 Introduction  
 Despite advances in modern cardiology, acute heart failure (AHF) remains a challenging 
problem in everyday clinical practice with growing incidence and unacceptably high morbidity and 
mortality (1). In the complex pathophysiology of AHF several mechanisms are involved, among 
which dysfunction or damage of multiple end-organs (ie. heart, kidney, liver) may play an 
important role with further ominous consequences for long-term outcomes (2). It has been well 
established that myocardial injury as evidenced by troponin release and deterioration in renal 
function occurring during an episode of AHF are both independent predictors of poor outcome (3-
5). Abnormalities in liver function have been recognized to accompany the natural course of 
chronic heart failure (6,7). Surprisingly however, the data on the prevalence and clinical 
significance of abnormalities in liver function tests (LFTs) in patients with AHF remain rather 
scarce (2,8-10).  Only recently, Ambrosy et al (9) have studied a population of AHF patients 
enrolled in the placebo arm of the EVEREST trial and demonstrated that abnormal LFTs are 
relatively common and carry important prognostic information. It has been subsequently confirmed 
by van Deursen et al (10) in AHF patients enrolled in the Pre-RELAX-AHF study. However, due to 
limited sample size and rather small number of events in this study, the prognostic impact of 
impaired LFTs needs further confirmation.   
 This study reports post-hoc analysis of patients enrolled in A Placebo-controlled 
Randomized study of the selective A1 adenosine receptor antagonist KW-3902 for patients 
hospitalized with acute HF and volume Overload to assess Treatment Effect on Congestion and 
renal funcTion (PROTECT) in order to evaluate the prevalence of abnormal LFTs, a pattern of 
changes in LFTs over time (from baseline to day 14) and their prognostic importance. 
 Methods 
 Inclusion/exclusion criteria and study design 
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 PROTECT was a global, prospective, multicentre, randomized, double-blind, placebo-
controlled trial that recruited 2033 patients hospitalized for AHF. A detailed description of the study 
design as well as results of the main study has been published elsewhere (11,12). For entry, patients 
were required to have dyspnea at rest or with minimal activity, at least one symptom of fluid 
overload (JVP>8cm or pulmonary rales ≥1/3 up the lung fields, not clearing with cough or ≥2+ 
peripheral edema, or pre-sacral edema) and elevated natriuretic peptide levels [brain natriuretic 
peptide (BNP) ≥500 pg/mL or N-terminal-pro-BNP (NT-proBNP) ≥2000 pg/mL].  All patients 
required intravenous (i.v.) loop diuretic therapy and had impaired renal function (as evidenced by 
estimated creatinine clearance of 20–80 mL/min by the Cockcroft–Gault equation corrected for 
weight in oedematous or obese subjects ≥100 kg). Relevant for the analysis exclusion criteria were 
known hepatic impairment (total bilirubin >3 mg/dL, albumin <2.8 mg/dL, or increased ammonia 
levels if performed), history of drug or alcohol abuse, clinical evidence of acute coronary syndrome 
in the 2 weeks prior to screening, ongoing or planned i.v. therapy for AHF with positive inotropic 
agents, vasopressors, vasodilators, or mechanical support with the exception of IV nitrates. Other 
exclusion criteria are outlined in the design paper (11).   
 Patients were randomized in a 2:1 ratio to receive either rolofylline 30 mg or placebo 
administered as a daily 4-hour infusion for 3 days in a double-blind manner.  
 Clinical assessments (heart failure signs and symptoms) were performed and blood for 
laboratory assessments was drawn daily just prior to the initial study drug/placebo  administration, 
through discharge and on days: 7 and 14. All laboratory tests were performed in a core laboratory. 
The study protocol included the following LFTs to be collected: AST [Aspartate aminotransferase], 
ALT [Alanine Aminotransferase] and albumin.   
 PROTECT fulfilled the requirements stated in the Declaration of Helsinki and it was 
independently approved by the Ethics Committees at each participating centre; written informed 
consent was obtained from each participant.  
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 Endpoints of the present analysis 
 The primary and secondary endpoints of PROTECT are presented in the design paper (11). The 
outcomes for this analysis were worsening of heart failure, worsening of renal failure within 7 days 
of  index hospital admission, in-hospital death and 180-day mortality. Worsening heart failure was 
reported based on worsening signs and symptoms of heart failure with resulting intensification of 
intravenous therapy for heart failure or mechanical circulatory or ventilator support. Worsening of 
renal failure was defined as a serum creatinine increase of ≥0.3 mg/dL (26.5 mmol/L) from 
randomization to Day 7, confirmed at Day 14, or the initiation of renal replacement therapy through 
Day 7.  
 For this analysis we defined the following cutoffs for abnormal LFTs: above upper limit of 
normal for AST or ALT (>37 U/L, and >47 U/L, respectively) or below lower limit of normal for 
albumin (<3.7 g/dL).  
 PROTECT showed a favorable effect of rolofylline neither with respect to the primary and 
secondary clinical composite end points, nor 60-day and 180-day mortality (12). As we were not 
aware of any data confirming that rolofylline may affect LFTs, the analysis was performed in the 
entire trial population.  
 Statistical analyses 
 Continuous variables are reported as mean ±  standard deviation for normally distributed 
variables and median (interquartile range, IQR) for non-normally distributed variables; categorical 
variables are reported as percentages. Differences between patients with abnormal and normal LFTs 
at baseline were tested for by using a two-sample t-test or Kruskal-Wallis rank test for continuous 
data and a Chi-square test for categorical data. 
 The association between baseline LFTs and worsening of HF, worsening of renal failure within 
7 days of the index admission, and in-hospital death was assessed using logistic regression analysis; 
the association between baseline and discharge LFTs and 180 day mortality was assessed using Cox 
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proportional hazards regression. The analyses were first performed by dichotomizing the LFTs into 
normal and abnormal and then repeated by including the LFTs as continuous variables. For the 
continuous analysis, possible non-linearity in the relationship between the LFTs and the outcomes 
of interest was explored using fractional polynomials, but this did not reveal any significant non-
linear relationships. The LFTs were therefore included as linear terms in the final models. To 
explore whether the associations in the univariable models were independent of other covariates, the 
following confounding factors were adjusted for in the multivariable analyses: gender, age, NYHA 
class, creatinine, sodium, systolic blood pressure, and hemoglobin. The analyses were performed on 
all patients from the PROTECT study for which complete covariate and outcome data were 
available. This resulted in a study population of 1,652 patients.  
 Liver function trajectories in PROTECT. 
 Changes in AST, ALT and albumin over time were modeled using linear mixed effects models, 
which assume the change in values over time can be described by a linear regression model 
including population-specific effects (fixed effects) and subject-specific effects (random effects). 
After visual inspection of the change in mean levels over time, several candidate models were fitted 
based on maximum likelihood maximization, assuming any missing data was missing at random. 
The best fitting model was subsequently selected by examining Akaike’s information criterion 
(AIC) and Bayesian information criterion (BIC) values for the models, which provide a measure for 
the relative quality of a model by balancing goodness-of-fit and model complexity. Due to the non-
normality of both AST and ALT distributions, a double log transformation was performed to allow 
more accurate modeling. For all three LFTs, the changes in mean levels over time (fixed-effects 
structure) were best described by a quadratic function. The random-effects structure of the models 
provided subject-specific intercepts and slopes for both linear and quadratic time effects. Both fixed 
and random effects were used to estimate subject-specific values and slopes at various time points. 
The effect of individual, subject-specific slopes at various time points – representing the rate of 
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change at those times – and change in LFTs on survival were examined using cox proportional 
hazards regression. All regression models were corrected for baseline values of the LFT in question. 
Multivariable models were corrected for covariates (as listed above). A two-sided p-value ≤ 0.05 
was considered to be statistically significant. All analyses were conducted using R-2.14.2. 
We applied this novel statistical modeling to describe trajectories of renal function in the 
PROTECT study and the method with detailed clinical interpretation is presented elsewhere (13).   
 Results 
 Prevalence of abnormal LFTs at baseline and during follow-up  
 Among 2033 patient enrolled in PROTECT, baseline AST, ALT and albumin were available in 
92%, 90% and 96% of patients, respectively. Baseline median (IQR) were for AST: 25 (14) U/L, 
for ALT: 21 (13) U/L and mean±SD  albumin was: 3.84± 0.43 g/dL. Abnormal baseline AST, ALT 
and albumin were present in 20%, 12% and 40% of patients, respectively. We observed decrease of 
prevalence of abnormal LFT reaching 15%, 9% and 26%, respectively at 14th day (Figure 1). 
 Patients characteristics  
 Baseline characteristics of the PROTECT population has been presented in detail elsewhere 
(12). Table 1 shows a comparison of baseline characteristics between patients with abnormal vs 
normal LFTs. Patients with elevated AST and ALT were younger, had lower incidence of 
comorbidities (hypertension, coronary artery disease and diabetes), lower systolic blood pressure 
and higher heart rate, higher hemoglobin, BUN and lower sodium on  admission, they received 
more often inotropes or vasopressors during hospital stay when compared to patients with normal 
AST or ALT. Patients with low albumin levels were slightly older, had more frequent incidence of 
diabetes, significantly elevated jugular venous pressure and magnitude of peripheral edema on 
physical examination, higher NT-proBNP, creatinine, and lower hemoglobin levels, received higher 
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doses of diuretics and more frequently inotropes or vasopressors during hospital stay when 
compared to those with normal albumin (see Table 1).     
 Clinical profile of patients with opposite LFTs trajectories  
 On day 3, the majority of patients (1320 (67%)) had decreasing trajectory of AST. This group 
did not differ in demographics, baseline clinical examination as well as in most biochemical 
parameters (creatinine, BUN, haemoglobin, natriuretic peptides values) when compared to patients 
with increasing trajectory of AST (see Table 2). However, we found that this group had higher 
baseline transaminases and albumin on admission, although the median/mean values remained 
within normal ranges (all p<0.001). Interestingly those two groups did not differ in treatment during 
hospitalization: diuretic doses, inotropes and vasodilatators use (see Table 2).  
 Sixty-one percent of patients (1197) had increasing trajectory of albumin on day 4. This group 
was significantly younger, had better renal function, lower haemoglobin and albumin on admission 
(all p<0.05) (see Table 2). Those patients had higher weight change during first 4 days of 
hospitalization (-3±3 vs -2.5±2.8, p<0.001). Interestingly patients with increasing trajectories of 
albumin received lower total dose of furosemidu within 7 days of hospitalization 260 [120-540] vs 
280 [160-560] p<0.02, whereas there was no difference in total dose of diuretic they received 
during first 3 days of treatment 240 [140-410] vs 240 [156-388.8] p=0.2 (see Table 2). Moreover, 
changes in albumin level between admission and discharge/day 7 significantly correlated with 
changes in hemoglobin levels (Rho= 0.542, p<0.001) and inversely in changes in body weight 
during first 4 days of hospital stay (Rho= -0.102, p<0.001). 
 Prognostic significance of baseline LFTs 
 There were 32 (1.9%) in-hospital deaths and 291 (17.6%) at 180 day follow-up, respectively.  
Abnormal baseline LFTs impacted neither the risk of worsening heart failure (odds ratios (OR), 
95% Confidence Interval (CI) – for AST: 1.3 (0.92 - 1.89), for ALT: 1.3 (0.85 - 2.04), for albumin: 
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1.19 (0.88 - 1.61), respectively, all p>0.05) nor worsening renal function during hospitalization (OR  
(95% CI) – for AST: 1.0 (0.71 - 1.40), for ALT:  0.70 (0.44 - 1.12), for albumin: 1.05 (0.80 - 1.38), 
respectively, all p>0.05).  
 We found a relationship between risk of in-hospital death and baseline levels of AST, ALT, 
and albumin, which remained significant after adjustment for the other prognosticators (details – see 
statistical analyses section) (Table 3a). Moreover, the multivariate model revealed that patients with 
abnormal LFTs on admission had significantly higher risk of in-hospital death when compared to 
patients with normal LFTs – ORs (95% CI) for abnormal AST, ALT, albumin were: 3.53 (1.70-
7.32), 3.89 (1.80-8.41), and 2.78 (1.32-5.87), respectively, (all p<0.01) (Table 3a).  
 Baseline values of AST, ALT and albumin were also related to the risk of 180-day all-cause 
mortality (Table 3b). After adjustment for other prognostic variables, we found that patients with 
abnormal baseline AST and albumin (but not ALT) had increased risk of 180-day mortality with 
hazard ratio (HR, 95%CI) of 1.33 (1.01-1.74) for AST and 1.44 (1.14-1.82) for albumin (both 
p<0.05) (Table 3b). 
 Prognostic significance of discharge LFTs 
 Values of AST, ALT and albumin on discharge/day 7 (whichever occurred first) were 
independently related to the risk of 180-day mortality (Table 4). Analogously, patients with 
abnormal LFTs at discharge had worse 180 day outcome in comparison to group with normal LFTs 
with HR (95%CI) for AST: 1.46 (1.07-1.98), for ALT: 1.50 (1.04-2.17), and for albumin: 1.61 
(1.24-2.11), respectively, all p<0.05 (Table 4).  
 Associations of LFTs trajectories and  180-day survival 
 To analyze the clinical consequences of rates of LFTs change during hospitalization we have  
examined the trajectories of LFTs change on day 3 (for transaminases) and on day 4 (for albumin) 
in relation to outcome. 
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 AST/ALT 
 AST and ALT slopes on day 3 were associated with 180-day mortality in univariable models 
(table 4), which remained significant after correction for covariates known to be associated with 
mortality HR (95% CI): 1.012 (1.006-1.019) and 1.008 (1.003-1.013), respectively (both p<0.001) 
(table 5). In other words, the steeper trajectory of AST/ALT increase at day 3 the higher risk of 180 
day mortality. 
 Albumin 
 Albumin slope on the 4th day of hospitalization showed a association with 180-mortality 
HR(95% CI): 0.342 (0.243-0.482) (p<0.001) (table 4), which persisted significant after 
multivariable correction HR(95% CI): 0.364 (0.245-0.541) p<0.001 (table 5). Patients with 
decreasing albumin trajectories on day 4 had significantly worse 180 day prognosis and the risk is 
increasing with decreasing albumin slope. 
 Figures 2 a-c show Kaplan-Meier curves for 180-day mortality stratified by trajectories 
categorized into rise versus fall on day 3 (for AST/ALT) and day 4 (for albumin).  
 Discussion 
 There are three major findings of the present analysis. Firstly, we found that abnormal LFTs are 
common in AHF, such abnormalities are present already on admission and decrease during 14 day 
observation. Secondly, an assessment of simple LFTs – AST, ALT and albumin performed at 
baseline and on discharge provides an important prognostic information. Thirdly, change of LFTs 
values during hospitalization is associated with clinical outcome.          
 We found relatively high prevalence of abnormal LFTs at baseline, although patients with 
known significant hepatic impairment (defined as total bilirubin >3 mg/dL, albumin <2.8 mg/dL, or 
increased ammonia levels if performed) were excluded from the study. Interestingly, we observed a 
much higher percentage of patients with hypoalbuminemia as compared to elevated 
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aminotransferases which may be explained by the patients’ profile. As the PROTECT study 
recruited AHF patients with dyspnea and signs of fluid overload, low albumin concentration may 
not only reflect hepatic synthesis insufficiency, but also constitute a biomarker of overhydratation, 
whereas elevated AST and ALT are rather markers of hepatocellular injury.  
 Further to this end, we observed decreased prevalence of abnormally elevated AST and ALT 
during 14 days of observation (although they were still present in about 10-15% of patients). It may 
well suggest that hepatocellular dysfunction/damage may constitute an integral element of several 
pathophysiological processes accompanying AHF, and standard therapies currently applied in AHF 
seem not to be able to reverse these abnormalities completely. We have previously reported lack of 
correlation between invasively monitored hemodynamic indices and AST/ALT in AHF patients 
(14), thus hemodynamic stabilization alone may not adequately improve LFTs. Although Ambrosy 
et al (9) found pattern of unchanged prevalence of abnormal LFTs (apart from bilirubin) within first 
7 days of hospitalization in AHF patients,  the authors observed decrease of prevalence of abnormal 
LFTs (except AP) during  8 week follow-up.    
 To the best of our knowledge, this is the first study showing that baseline as well as 
discharge/day 7  LFTs (AST/ALT and albumin) are independent predictors of short- and long-term 
mortality in AHF population. Earlier, post-hoc analysis of the EVEREST study revealed that low 
baseline albumin and elevated bilirubin, but not elevated AST/ALT were associated with clinical 
outcome (9). Van Deursen (10) reported changes in albumin from baseline to day 5 as predictors of 
mortality, but due to small number of events no multivariable adjustment was performed in this 
study. On the other hand retrospective analysis of SURVIVE study (the study included AHF 
patients that would be excluded from PROTECT as they required inotrope support) revealed that 
abnormal baseline transaminases were related to poor outcome (15). Although, patients with 
significant liver dysfunction were excluded from the PROTECT study we found that even mild to 
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moderate abnormalities in LFTs indentify patients at higher risk of death: in-hospital as well as 
during first 180 days of the follow-up.   
 Pathophysiological mechanisms explaining the relationship between abnormal LFTs and poor 
outcome remain unclear. Surprisingly, abnormal baseline LFTs were not associated with higher risk 
of either heart failure or renal function worsening during hospitalization, which are traditionally 
linked with higher risk of short- and longer-term mortality (5,16). We may speculate that elevated 
AST/ALT and low albumin at baseline are laboratory surrogates reflecting some clinical 
characteristics which may be potentially associated with poor outcome (for AST/ALT - lower 
systolic blood pressure, higher heart rate, lower sodium, more frequent use of inotropes or 
vasopressors, for albumin – low hemoglobin, low sodium, more severe fluid overload, higher dose 
of diuretics) (17). Since low ALT may be related to worse outcome in some populations (especially 
in elderly), there were premises to believe that risk related to transaminases can have a U-shape 
pattern (18). Based on our data there is no evidence to support such a hypothesis, as we have 
confirmed linear increase in risk of death with increasing transaminases and decreasing albumin.  
Moreover, we found that categorization into normal and abnormal LFTs identifies groups of 
patients with much worse prognosis, i.e. patients with abnormal baseline LFTs had approximately 
three times higher risk of in-hospital death in comparison to patients with normal LFTs. We decided 
to show these analyses as they provide simple and useful clinical information that can be helpful in 
everyday practice.      
 As we believe that day to day changes in absolute values of LFTs during hospitalization are 
complex to calculate and difficult to interpret in a meaningful biological context, we focused our 
interest on analysis of LFTs’ trajectories during first days of hospitalization. The slopes of LFTs’ 
change were analyzed on the 3rd day (for AST/ALT) and the 4th day for albumin as that may reflect 
the effectiveness of the initial treatment. The trajectories as a result of complex calculations  not 
only describe the direction of LFTs’ change (increase vs decrease) but also the rate of change (the 
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higher trajectory value (the steeper the trajectory) the greater and the faster change of LFT). We 
have previously reported interesting clinical findings using this approach directed towards changes 
renal function in PROTECT study (13).  
  Our results support the hypothesis that increasing AST/ALT as well as decreasing albumin 
early during hospitalization are independent biochemical signs of poor prognosis. Moreover the 
analysis revealed that the greater change of LFTs (increase of AST/ALT, decrease of albumin) the 
worse the prognosis is. Presented Kaplan-Meier curves showed that simple categorization of LFTs 
trajectories as increase vs decrease at examined time points can identify patients with significantly 
worse outcome (for AST and albumin). However this was not true for ALT, for which different 
cutoff should be found. As we remember that serial assessments of LFTs during hospitalization is 
not a routine or recommended procedure in AHF patients,  based on our results, it seems reasonable 
to monitor LFTs values (at least in some patients) as it may bring additional clinical information. To 
the best of our knowledge, this is the first study showing that dynamic change of LFTs and rate of 
its change during hospitalization has significant prognostic importance.   
 Interestingly, comparison of patients with opposite trajectories of albumin showed that the 
group with increasing albumin received lower total dose of furosemide during 7 days of 
hospitalization, whereas the same dose within first 3 days of treatment. That observation may 
suggest that those patients had better early response to the same doses of furosemide that lead to 
lower furosemide demand after the 3rd day. That speculation is also supported by observation that 
those patients had significantly higher weight loss during first 4 days of hospitalization.  
As already mentioned, hypoalbuminemia may not only reflect liver function itself, but also 
effectiveness of dehydration. Indeed, we found a correlation between makers of body fluid status 
(changes in body weight and hemoglobin concentration) and changes in albumin levels during 
hospitalization. Moreover patients with increasing trajectory of albumin had lower baseline albumin 
as well as haemoglobin which can suggest that those phenomena were at least in part a results of 
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overhydratation. It has been already shown that hemodilution may be responsible for low 
hematorcrit (dilutional anemia) in patients with advanced heart failure (19). Similarly, some patients 
with low albumin at baseline may in fact have dilutional (relative) hypoalbuminemia due to fluid 
overload. They do not necessarily have at the same time liver dysfunction (defined as abnormal 
liver synthesis capacity) and the absolute albumin amount may well be within normal range. 
Baseline characteristics of patients with hypoalbuminemia (higher NT-proBNP, lower hemoglobin 
and sodium concentration, clinical evidence of more extensive fluid overload) as well as fact that 
patients with increasing trajectory of albumin had lower albumin at baseline also indicate that 
dilution may play an important role in developing hypoalbuminemia. Hypoalbuminemia has already 
been shown to be a strong prognosticator of adverse long-term outcome in patients with chronic 
heart failure (20,21), but prognostic significance of low albumin in the AHF settings has not yet 
been adequately explored.   
 Thus, patients with low albumin on discharge/day 7 might have either ineffective decongestion 
or real hypoalbuminemia due to liver dysfunction, which was independently related to worse 
outcome (at 180 days). In accordance with  previous data, we found that patients with decreasing 
albumin during hospitalization (reflecting ineffective decongestion or lack of liver function 
improvement) had significantly higher risk of death during follow-up when compared to patients 
with an increase in albumin.   
 Study limitations.  
 As this is a post-hoc analysis of the selected population included  into clinical trial, it may not 
completely reflect the scale of the problem of liver dysfunction in the whole spectrum of AHF 
patients. Additionally, we have only assessed 3 LFTs – albumin (reflecting liver synthesis capacity) 
and AST/ALT (reflection hepatocellular injury). For more comprehensive characteristics additional 
LFTs reflecting cholestatic pattern would be useful.   
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Figure legends 
Figure 1.  
Percentage of patients with abnormal LFTs overtime (until day 14). 
 
Figure 2.  
Kaplan Meier curves for 180-day mortality by LFTs slopes rise vs fall (on Day 3 for AST/ALT and 
day 4 for albumin). a) AST, b) ALT, c) albumin. 
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Table 1.  
Comparison of characteristics of patients with abnormal vs normal LFTs at baseline. 
Variable 
Elevated 
AST 
n = 370 
Normal 
AST 
n = 1508 p-value 
Elevated 
ALT 
n = 221 
Normal 
ALT 
n = 1609 p-value 
Low albumin 
n = 788 
Normal 
albumin 
n = 1167 p-value 
Demographics 
Age (years) 69+/-12.9 70.5+/-11.2 0.05 67.7+/-13.1 70.4+/-11.4 <0.01 70.8+/-11.3 69.7+/-11.8 0.04 
Sex (male, %) 63.8 67.4 0.18 67.9 66.7 0.73 65.2 67.7 0.26 
White race (%) 94.3 95.8 0.21 94.5 95.6 0.47 92.7 97.4 <0.01 
Measurments 
Body-mass index 28.3 +/-6.2 28.9+/-6.1 0.09 27.9+/-6.2 29+/-6.2 0.02 28.8+/-6.5 28.9+/-5.9 0.74 
LVEF (%) 31.2+/-14.4 32.3+/-12.7 0.35 27.1+/-12.2 32.8+/-13 <0.01 32.2+/-13.3 32.2+/-12.8 0.95 
NTproBNP (pg/ml) 3000 [606] 3000 [935] 0.13 3000 [1083] 3000 [922] 0.1 3000 [1191] 3000 [712] <0.01 
BUN (mg/dl) 31 [19] 29 [19] <0.01 32 [22] 29 [19] 0.06 32 [21] 28 [17] <0.01 
HGB (g/dL) 13.2+/-2 12.5+/-2 <0.01 13.1+/-2.1 12.6+/-2 <0.01 12.2+/-2 13+/-1.9 <0.01 
Na (mmol/l) 138.5+/-4.6 139.5+/-4 <0.01 138.6+/-4.4 139.4+/-4.1 0.01 138.8+/-4.4 139.7+/-3.9 <0.01 
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Creatinine (mg/dl) 1.5+/-0.5 1.5+/-0.6 0.08 1.5+/-0.6 1.5+/-0.6 0.95 1.6+/-0.6 1.5+/-0.5 <0.01 
Medical history (%) 
Hypertension 74.3 80.4 <0.01 71 80.4 <0.01 81.5 77.9 0.06 
Ischemic heart disease 64.1 70.6 0.02 58.8 70.8 <0.01 69.1 69.8 0.73 
Myocardial infarction 42.2 50.6 <0.01 43.4 49.6 0.09 48.3 50.2 0.43 
Atrial fibrillation 56.6 53.9 0.35 52.7 54.7 0.58 54.1 54.7 0.77 
Diabetes 34.6 48.6 <0.01 36.2 47.4 <0.01 49 43.2 0.01 
Clinical examination at baseline 
Systolic Blood Pressure 
(mmHg) 121.5+/-17.4 124.9+/-17.7 <0.01 120.1+/-16.8 124.8+/-17.8 <0.01 124+/-18 124.7+/-17.4 0.39 
Diastolic Blood Pressure 
(mmHg) 74.4+/-12.2 73.6+/-11.9 0.27 74.1+/-11.9 73.7+/-12 0.66 73.5+/-12.3 74.1+/-11.5 0.32 
HR (beat/min.) 83.4+/-16.6 79.5+/-15.1 <0.01 83.8+/-17.2 79.8+/-15.2 <0.01 81.3+/-15.9 79.5+/-15.1 0.02 
JVP (%)   0.69   0.64   0.05 
< 6 cm 11.4 12.3  11.6 12.1  11 12.4  
6 - 10 cm 46.3 48  45.3 48.3  44.5 49  
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> 10 cm 42.3 39.7  43.2 39.6  44.5 38.6  
Edema (%)   0.55   0.54   <0.01 
0 13 14.5  12.2 14.2  10 17  
1+ 17.3 18.6  18.6 18.2  14.6 20.6  
2+ 43.5 39.5  44.3 39.8  39.2 41  
3+ 26.2 27.4  24.9 27.7  36.2 21.4  
Pulmonary congestion (%)   0.8   0.53   0.23 
No rales 9.2 9.6  11.8 9.2  10.4 8.9  
Rales < 1/3 28.9 29.6  29.9 29.5  30.5 28.2  
Rales 1/3 - 2/3 50.5 51.2  47.5 51.5  48.7 53.4  
Rales > 2/3 11.4 9.6  10.9 9.8  10.3 9.5  
Treatment before hospital admission (%) 
ACE-inhibitor /ARB 75.7 75.2 0.84 77.4 74.9 0.43 72.1 78 <0.01 
Beta blockers 75.4 77.4 0.42 79.6 76.7 0.33 74.1 78.2 0.04 
Nitrates 24.6 25.8 0.63 19 26.5 0.02 27.4 24.7 0.18 
Aldosterone inhibitor 44.1 44.1 0.98 43.9 44.2 0.93 40.7 46.7 <0.01 
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Prior digoxin 26.2 28.7 0.34 27.1 28.4 0.71 26.6 29.7 0.15 
Treatment through day 7 
Total loop diuretics (mg) 287 [495] 280 [432] 0.06 280 [500] 280 [420] 0.8 320 [559] 240 [360] <0.01 
Inotropes or vasopressors 10 6.6 0.02 9.5 6.9 0.16 9.4 5.7 <0.01 
Vasodilators 9.5 8.8 0.7 9.5 8.5 0.6 9.8 8.1 0.19 
Medications at discharge (or day 7, if earlier) (%) 
ACE-inhibitor /ARB  81.1 82.1 0.68 83.4 81.6 0.52 79.8 84.2 0.01 
Beta blockers  84.5 85.2 0.75 87.2 85.1 0.42 81.6 86.7 <0.01 
Nitrates  19.2 20.6 0.53 14.2 21.3 0.02 23.2 18.4 <0.01 
Aldosterone inhibitor  61.4 59.3 0.46 63 59.2 0.28 58.9 61.5 0.24 
Digoxin  32.4 33 0.82 35.1 32.5 0.46 33.1 33.2 0.97 
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Table 2 
Comparison of characteristics of patients by opposite AST and albumin trajectories.  
Variable Decreasing slope Increasing slope  P-value Decreasing slope Increasing slope P-value 
 AST ALBUMIN 
Number of patients 1320 642   766 1197   
Demographics       
Age (years) 70.4±11.7 69.4±11.4 0.064 70.9±11.4 69.5±11.7 0.005 
Sex (male, %) 66.4 (876) 68.5 (440) 0.363 64.9 (497) 68.5 (820) 0.106 
Measurments       
LVEF (%) 32.3±13.3 32.2±12.4 0.939 33.2±13.2 31.7±12.9 0.091 
Creatinine (mg/dL) 1.4 [1.1-1.8] 1.4 [1.1-1.8] 0.610 1.4 [1.2-1.9] 1.4 [1.1-1.7] <0.001 
Creatinine Clearance (ml/min) 48.4 [36.7-63.4] 49.5 [36.6-63.4] 0.801 45.9 [35.8-59.9] 51.5 [37.8-65.2] <0.001 
Blood Urea Nitrogen (mg/dL) 29 [22-41] 29 [21-41] 0.363 31 [23-44] 28 [21-39] <0.001 
Sodium (mmol/L) 140 [137-142] 140 [137-142] 0.639 140 [137-142] 140 [137-142] 0.601 
Hemoglobin (g/dL) 12.7±2 12.7±2 0.930 12.9±2.1 12.5±1.9 <0.001 
Total Cholesterol (mmol/L) 149.2±44.8 143.7±42.9 0.010 152.2±44.8 144.2±43.6 <0.001 
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Triglycerides (mmol/L) 103.6±56.7 98.4±52.2 0.048 104.8±58.4 100±53.2 0.065 
NT-proBNP (pg/mL) 
3000 [3000-
3864.8] 3000 [3000-3853] 0.642 
3000 [3000-
4033.8] 
3000 [3000-
3781.8] 0.966 
BNP (mg/dL) 
1301.5 [812.5-
2265] 
1198.5 [834-
2094.8] 0.353 
1158.1 [761.2-
2090] 
1304 [841.2-
2260.2] 0.127 
AST (U/L) 26 [21-36] 22 [17-28] <0.001 25 [20-33] 24 [19-33] 0.104 
ALT (U/L) 22 [16-36] 19 [13-26] <0.001 21 [15-32] 21 [14-32] 0.311 
Albumin (mg/dL) 3.9±0.4 3.8±0.4 <0.001 4±0.4 3.8±0.4 <0.001 
Clinical examination at baseline       
Systolic Blood Pressure (mmHg) 124.3±17.4 124.8±18.1 0.625 125.2±17.3 124±17.8 0.121 
Diastolic Blood Pressure (mmHg) 73.7±11.5 74.2±12.4 0.391 74.4±11.2 73.4±12.2 0.053 
Heart Rate (beats/min) 79.6±15.1 80.8±16 0.135 80.5±15.7 79.7±15.2 0.275 
Rolofylline administration (%) 66.4 (877) 67.9 (436) 0.549 65.1 (499) 68.1 (815) 0.193 
Atrial fibrillation on presentaiton 39.7 (212) 45.6 (115) 0.134 43.1 (127) 40.7 (200) 0.573 
Orthopnea (%) 96.9 (1261) 94.3 (597) 0.011 96.3 (731) 95.8 (1128) 0.688 
Rales (%) 61.2 (806) 59.5 (381) 0.510 63.4 (486) 58.9 (702) 0.049 
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Edema (%) 66.7 (880) 69.3 (444) 0.280 66.8 (512) 68 (813) 0.616 
NYHA Class   0.105   0.128 
I-II 17.7 (233) 15.4 (99)  17.8 (136) 16.4 (196)  
III 49.1 (648) 46.9 (301)  45.4 (348) 50.3 (602)  
IV 28 (370) 32.4 (208)  31.2 (239) 28.3 (339)  
Clinical Outcomes       
Weight change day 1 - 4 (kg) -2.7±2.8 -3±3.2 0.037 -2.5±2.8 -3±3 <0.001 
Total diuretic dose, day 1 - 3 (mg)  240 [140-400] 240 [140-400] 0.703 240 [156-388.8] 240 [140-410] 0.219 
Total IV diuretic dose through day 7 
(mg) 280 [133.3-560] 280 [120-539.8] 0.738 280 [160-560] 260 [120-540] 0.015 
Inotropics (%) 5.8 (76) 7 (45) 0.326 8.9 (68) 4.4 (53) <0.001 
Inotropics or vasodilators (%) 14.8 (195) 17.6 (113) 0.121 17.2 (132) 14.7 (176) 0.150 
Residual Congestion on day 7 (%) 57.8 (355) 61.9 (185) 0.526 70.6 (229) 51.7 (311) <0.001 
WRF, day 7 (%) 20.7 (264) 25.2 (158) 0.032 20.4 (154) 23.3 (268) 0.148 
WRF, day 14 (%) 22.9 (292) 24.4 (153) 0.504 23.2 (175) 23.5 (271) 0.897 
Persistent WRF (%) 12.9 (165) 14 (88) 0.556 13.1 (99) 13.4 (154) 0.915 
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Treatment failure due to Worsening 
Heart Failure (%) 8.7 (115) 10 (64) 0.410 12.4 (95) 7 (84) <0.001 
Treatment failure due to WRF (%) 12.6 (161) 13.6 (85) 0.616 13 (98) 12.9 (148) 0.972 
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Table 3.   
Baseline LFTs as predictors of:  
a) in hospital mortality 
 Univariate model Multivariate model* 
Baseline LFTs OR (95% CI) p-value OR  (95% CI) p-value 
AST (for a unit 
increase of 100U) 
1.583  (1.219 – 2.057) <0.001 1.486  (1.107 – 1.996) 0.008 
ALT (for a unit 
increase of 100U) 
1.297 (1.048 – 1.605) <0.001 1.293 (1.047 – 1.597) 0.017 
Albumin (per decrease 
of 1 g/dl) 
4.65 (2.23-9.6) <0.001 5.4  (2.49- 11.76) <0.001 
Baseline LFTs as categorized variables 
Abnormal AST (cut-off 
value of 37 U/L)** 
4.205 (2.079 – 8.504) <0.001 3.525 (1.697 – 7.322) <0.001 
Abnormal ALT (cut-off 
value of 47 U/L)** 
4.071 (1.931 – 8.583) <0.001 3.891 (1.800 – 8.413) <0.001 
Low Albumin (cut-off 
value of 3.7 g/dL)** 
2.619 (1.271 – 5.395) <0.001 2.784 (1.320 – 5.874) 0.007 
* adjusted for (age, gender, NYHA class, serum creatinine, serum Na+, Blood pressure, 
HGB);  
** group of patients with normal AST, ALT, albumin are reference.  
 
b) 180 day mortality 
 Univariate model Multivariate model* 
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Baseline LFTs HR (95% CI) p-value HR (95% CI) p-value 
AST (for a unit 
increase of 100U) 
1.253 (1.128 – 1.391) <0.001 1.132 (1.016 – 1.262) 0.025 
ALT (for a unit 
increase of 100U) 
1.154 (1.066 – 1.250) <0.001 1.115 (1.026 – 1.213) 0.011 
Albumin (per decrease 
of 1 g/dl) 
1.89  (1.47-2.445) <0.001 1.675 (1.279-2.198) <0.001 
Baseline LFTs as categorized variables 
Abnormal AST (cut-off 
value of 37 U/L)** 
1.464 (1.120 – 1.947) 0.005 1.325 (1.006 – 1.744) 0.0453 
Abnormal ALT (cut-off 
value of 47 U/L)** 
1.242 (0.886 – 1.742) 0.21 1.137 (1.024 – 1.047) 0.46 
Low Albumin (cut-off 
value of 3.7 g/dL)** 
1.631 (1.296 – 2.053) <0.001 1.437 (1.137 – 1.818) 0.002 
* adjusted for (age, gender, NYHA class, serum creatinine, serum Na+, Blood pressure, 
HGB) 
** group of patients with normal AST, ALT, albumin are reference.  
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Table 4.  
Discharge LFTs as predictors of 180-days mortality. 
 Univariate model Multivariate model* 
Baseline LFTs HR (95% CI) p-value HR (95% CI) p-value 
AST (for a unit 
increase of 100U) 
1.160 (1.053 – 1.279) 0.003 1.156 (1.034 – 1.294) 0.011 
ALT (for a unit 
increase of 100U) 
1.170 (1.087 – 1.259) <0.001 1.114 (1.031 – 1.205) 0.007 
Albumin (per decrease 
of 1 g/dl) 
2.165 (1.63-2.865) <0.001 1.786 (1.32-2.4) <0.001 
Discharge LFTs as categorized variables 
Abnormal AST (cut-off 
value of 37 U/L)** 
1.481 (1.097 – 1.999) 0.01 1.456 (1.072 – 1.976) 0.016 
Abnormal ALT (cut-off 
value of 47 U/L)** 
1.65 (1.151 – 2.366) 0.006 1.504 (1.042 – 2.169) 0.029 
Low Albumin (cut-off 
value of 3.7 g/dL)** 
1.928 (1.484 – 2.505) <0.001 1.613 (1.235 – 2.108) <0.001 
* adjusted for (age, gender, NYHA class, serum creatinine, serum Na+, Blood pressure, 
HGB) 
** group of patients with normal AST, ALT, albumin are reference. 
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Table. 5    
LFTs trajectories as predictors of 180 day outcomes.  
 
 
LFTs trajectories HR (95% CI) P HR (95% CI) P 
Univariate Cox regression Multivariable Cox regression 
AST (day 3) 1.015 (1.009-1.02) <0.001 1.012 (1.006-1.019) <0.001 
ALT (day 3) 1.01 (1.007-1.014) <0.001 1.008 (1.003-1.013) 0.001 
Albumin (day 4) 0.342 (0.243-0.482) <0.001 0.364 (0.245-0.541) <0.001 
models are all corrected for the baseline value of LFTs 
